Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Helen Heslop, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00073879
First received: December 10, 2003
Last updated: January 27, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2004
  Primary Completion Date: April 2004 (Final data collection date for primary outcome measure)